In September 2023, The US Food and Drug Administration has approved Krystal Biotech’s Investigational New Drug (IND) ...

Are you searching for effective medications to treat 'Alpha-1 Antitrypsin Deficiency'? This comprehensive guide provides the latest information on medications-both generic and branded-that are ...

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency ... on a brand new treatment modality allowed ...

Moderna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference.

Korro Bio (KRRO) announced the initiation of dosing in its REWRITE study investigating KRRO-110 as a potential treatment for individuals with ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025Alvelestat, for ...

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

Owing to the latest portfolio reorganization, Intellia has decided to stop the development of its in vivo gene insertion candidate, NTLA-3001, for the treatment of alpha-1 antitrypsin deficiency ...